Contrave versus Qsymia: compare the components and monitoring, not just the pill format

Contrave combines naltrexone with bupropion; Qsymia combines phentermine with topiramate in an extended-release product. Both have FDA-approved weight-management uses, but their labeled populations, contraindications, interactions and monitoring differ. Choosing between them requires an individual clinical assessment, not a comparison based only on being oral medicines or on weight-loss percentages from separate trials.¹²³

Start with two ingredient lists

The combination matters. Contrave is not simply an antidepressant prescription, and Qsymia is not the same product as phentermine alone. Their labels describe specific formulations and uses; a separately prescribed ingredient is not automatically a substitute for the fixed combination.¹²

Bring a complete medication list to the consultation, including products used for pain, mood, seizures, sleep and other weight-management treatment. The prescriber needs to identify duplicate ingredients and clinically important interactions before discussing which option might fit.

The population also matters: Contrave’s weight-management indication is for adults meeting its criteria; Qsymia’s label includes qualifying adults and pediatric patients aged 12 and older with obesity.¹² This is not a reason to infer that either medicine is appropriate for any particular person in those age groups.

Two different screening conversations

These are selected decision points, not complete safety lists or a self-screening checklist. Each medicine’s full prescribing information remains the reference for the clinician.¹² A history that requires discussion should not be reduced to an online yes/no selector.

Why opioid exposure deserves an explicit question

Contrave contains an opioid antagonist. Its label contraindicates chronic opioid use and describes concerns involving opioid blockade, withdrawal and overdose vulnerability. It also addresses intermittent opioid treatment and procedures that may require pain management.¹

Tell the prescriber about all relevant medicines and any planned procedure. Do not try to overcome blockade by taking more opioid medicine, and do not use this comparison to design a medication-free interval. The prescribing and procedural teams need a coordinated plan.

Ask what information an emergency or surgical team should have in the medication record. This is a practical difference from comparing pills by convenience: a product can affect care delivered by another clinician even when the weight-management visit itself is straightforward.

Qsymia has a specific pregnancy-risk program

Qsymia is contraindicated in pregnancy because of fetal risk associated with topiramate. Its label recommends pregnancy testing before treatment and monthly during treatment for patients who can become pregnant, and it is distributed through certified pharmacies under a REMS program.²

Ask the prescriber to explain the current program, reproductive planning, and what to do if pregnancy occurs. Do not treat this as a routine checkbox or assume another weight-management medicine shares the same program.

Weight-loss treatment during pregnancy is a separate clinical issue for either option. The important distinction here is that Qsymia’s named risk-management requirements are not interchangeable with Contrave’s labeling. Use the current product-specific instructions rather than an old class comparison.

Compare the care plan before comparing trial averages

Separate studies can differ in baseline health, treatment duration, adherence, lifestyle support, analysis method and dropout. A larger percentage on one product’s trial page does not, by itself, establish the better choice for an individual. NIDDK emphasizes health history, side effects, other medicines and the broader treatment plan when selecting weight-management medication.³

Ask what response the clinician will evaluate, when it will be reviewed, and how tolerability or inadequate response changes the plan. Both labels contain response-based reassessment instructions; these should be interpreted by the prescriber rather than turned into a home escalation schedule.¹²

Cost comparisons should include the actual prescription, required follow-up, testing when applicable and coverage conditions. A membership fee that excludes medicine or monitoring is not directly comparable with an all-in quote. Ask the practice to name what it supplies and what another provider or pharmacy bills separately.

Leave with an accountable prescriber and a change plan

When exploring medical weight-management practices, identify who reviews contraindications, handles medication interactions and responds between visits. Verify the named practitioner’s license separately from the program’s marketing.

A useful consultation ends with a reasoned explanation of why the proposed medicine fits the health history, what will be monitored, and what would prompt reconsideration. The decision is not simply “Which pill causes more weight loss?” It is “Which complete treatment plan can be used and followed appropriately in my circumstances?”